Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development

Abstract

Recent progress in understanding the molecular basis of cancer has redefined the landscape for cancer drug discovery and development. Among the most exciting and promising benefits are molecular targeted cancer therapies, which can be seen as progress toward personalized medicine for cancer patients

Keywords

Drug developmentMechanism (biology)Surrogate endpointMedicineDrugOncologyIntensive care medicinePharmacologyInternal medicine

MeSH Terms

AnimalsAntineoplastic AgentsBiomarkersTumorClinical Trials as TopicDrug DesignDrug IndustryHumansNeoplasmsResearch Support as Topic

Affiliated Institutions

Related Publications

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

Sharon Barr , Stuart Thomson , Elizabeth Buck +10 more

Over 90% of all cancers are carcinomas, malignancies derived from cells of epithelial origin. As carcinomas progress, these tumors may lose epithelial morphology and acquire mes...

2008 Clinical & Experimental Metastasis 199 citations

Publication Info

Year: 2004
Type: review
Volume: 10
Issue: 11
Pages: 3885-3896
Citations: 156
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

156

OpenAlex

Influential

140

CrossRef

Cite This

APA Style

                            
                                
                                    John W. Park, 
                                
                                    Robert S. Kerbel, 
                                
                                    Gary J. Kelloff
                                
                                et al.
                            
                            (2004). 
                            Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development. 
                            Clinical Cancer Research
                            , 10
                            (11)
                            , 3885-3896.
                            https://doi.org/10.1158/1078-0432.ccr-03-0785
                        

Identifiers

DOI: 10.1158/1078-0432.ccr-03-0785
PMID: 15173098

Data Quality

Data completeness: 86%